All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-GD2 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human GD2. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-GD2 antibody linked to 41BB and CD3ζ signaling domains. And the vector product was designed for the treatment of Neuroblastoma.
CAR Construction : Fig.1 Flow cytometry results showing GD2 expression in TNBC cell lines using clone Dinutuximab. SUM159 and Hs 578T cells were stained with an APC-conjugated anti-GD2 antibody (clone 14.G2a), dinutuximab. Ly, S., Anand, V., El-Dana, F., Nguyen, K., Cai, Y., Cai, S., ... & Battula, V. L. (2021). Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells. Journal for immunotherapy of cancer, 9(3). |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-GD2 (Dinutuximab) scFv h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-MZ054). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION